BioTime Provides Financing And Product Development Update

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) today announced the results of its capital raising activities since October 1, 2013 through its $25 million Controlled Equity Offering facility, and through sales of BioTime common shares by certain of its subsidiaries, in “at-the-market” transactions through Cantor Fitzgerald & Co., as sales agent. BioTime and its majority owned subsidiaries, LifeMap Sciences, Inc., Cell Cure Neurosciences, Inc. and OncoCyte Corp. raised gross proceeds of approximately $12.6 million, in the aggregate, from the sale of approximately 3.31 million common shares at a weighted average price of $3.81 per share in the open market, including approximately $8.5 million since January 1, 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news